{"url_path":"/sec/armp/8-k/2026-07-20/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/921114/0001104659-26-084860-index.html","accession_number":"0001104659-26-084860","cik":"0000921114","ticker":"ARMP","issuer_name":"Armata Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/921114/0001104659-26-084860-index.html","primary_entity_key":"0000921114","primary_entity_name":"Armata Pharmaceuticals, Inc."},"word_count":636,"has_tables":true,"body_markdown":"**Item 5.02**\n**Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nOn July 17, 2026, the Board of Directors (the “*Board*”)\nof Armata Pharmaceuticals, Inc. (the “*Company*”) promoted and appointed David House as the Company’s Chief Financial\nOfficer, effective July 17, 2026. Mr. House previously served as the Company’s Senior Vice President, Finance and principal financial\nofficer since August 2024. Biographical information regarding Mr. House required by Item 401 of Regulation S-K was previously reported\nin the Company’s most recent definitive proxy statement filed with the SEC on April 27, 2026.\n\n \n\nIn connection with Mr. House’s appointment\nas Chief Financial Officer, the Company and Mr. House entered into an employment letter agreement, dated July 17, 2026 (the “*House\nAgreement*”), which confirms the terms of Mr. House’s continued employment with the Company from and after the date thereof.\nPursuant to the House Agreement, Mr. House will serve as the Company’s Chief Financial Officer, reporting directly to the Company’s\nChief Executive Officer.\n\n \n\nPursuant to the House Agreement, Mr. House will receive an annual base\nsalary of $371,315, and will be eligible for a target annual bonus opportunity equal to 50% of his base salary, with the actual bonus\npayable based on actual performance as determined by the Board or compensation committee. Mr. House’s annual target performance\nbonus percentage is subject to increase, but not decrease, from time to time in the discretion of the Board or the compensation committee.\n\n \n\nThe House Agreement provides that Mr. House will\nbe eligible to receive annual equity awards pursuant to the Company’s 2016 Equity Incentive Plan or any successor plan commencing\nin 2026. The House Agreement states that the current intent of the compensation committee is to provide Mr. House with an equity award\neach fiscal year, commencing in 2026, with a grant date fair value of approximately $300,000, but Mr. House is not entitled to any specific\naward or terms, and any such awards will vest on the same basis as equity awards granted to other senior executives in respect of any\nfiscal year.\n\n \n\nThe House Agreement provides that, if the Company\nterminates Mr. House’s employment without “Cause” (as defined in the House Agreement) other than due to his death or\ndisability, or if Mr. House resigns for “Good Reason” (as defined in the House Agreement), then, subject to his execution\nof a separation agreement and general release of claims and continued compliance with his post-employment restrictive covenants, Mr. House\nwill continue to receive his then-current base salary for 12 months following such termination. If Mr. House experiences an involuntary\ntermination within one month prior to, or 12 months following, a “Change in Control” (as defined in the House Agreement),\nthe vesting of all of his outstanding equity awards that are subject to time-based vesting requirements will accelerate in full as of\nthe date of such involuntary termination or, if later, the Change in Control.\n\n \n\nOn July 17, 2026, the Company and Pierre Kyme, the Company’s\nChief Business Officer, agreed to conform the definition of “change in control” in Mr. Kyme’s Employment Letter Agreement,\ndated June 1, 2024 (the “*Kyme Agreement*”) to the definition in the House Agreement (and other agreements with senior\nexecutives of the Company). The Kyme Agreement remains in full force and effect in accordance with its terms with this modified definition.\n\n \n\nThe foregoing descriptions of the House Agreement\nand the modification of the Kyme Agreement (the “*Kyme Amendment*”) do not constitute complete summaries of the terms\nof the House Agreement or the Kyme Amendment and are qualified in their entirety by reference to the full text of the House Agreement\nand the Kyme Amendment, which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and incorporated herein\nby reference.\n\n \n\n- 2 -"}